Interview

Neurodegenerative disorders
#Alzheimer's #Cognition Therapeutics #Interview #Neurodegenerative disorders #Neuroscience

How pharma is targeting advances in Alzheimer’s treatments

Listen to this article on the DDW Podcast: Cognition Therapeutics recently completed the enrolment of its Phase II SEQUEL trial for patients with mild-to-moderate Alzheimer’s disease. The focus of the trial is to test Cognition Therapeutics’ experimental drug, CT1812 for patients with dementia with Lewy… Read More

#Exclusive Content

#Absci #AI / data analytics / healthtech / informatics #Antibodies #Artificial intelligence (AI) #Drug discovery #Interview

How generative AI could improve drug discovery

Listen to this article on the DDW Podcast: Absci is a generative artificial intelligence (AI) drug creation company with goals of bringing better biologics to patients more quickly. Here, DDW Editor Reece Armstrong speaks to Sean McClain, the Founder and CEO of Absci about how generative AI… Read More

#Exclusive Content

#Cancer research #Cancer Research Horizons #Interview

New podcast: Cancer research at the academic/industry interface

The latest sponsored DDW Sitting Down With podcast is now available for your listening pleasure. The podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer… Read More

#News

#Cancer research #Cancer Research Horizons #Interview #Sitting Down With #Sitting Down With podcast

How Cancer Research Horizons is innovating through its academic and industry interface

The latest sponsored DDW Sitting Down With podcast features Steve Wedge, Chief Scientific Officer of Cancer Research Horizons and Mike Waring, Head of Academic Medicinal Chemistry at Cancer Research Horizons. They discuss the work Cancer Research Horizons is conducting at its site in Newcastle University; how Cancer Research… Read More

#Podcasts

#Cancer research #CAR-T #Immunotherapy #Interview #Meet the Researcher #Oncology

Meet the researcher: John Maher, Leucid Bio

Listen to this article on the DDW Podcast: John Maher, Leucid Bio, tells Megan Thomas about his work and offers valuable advice to others in this field. MT: Where do you work, and can you tell us what you’re working on at the moment?… Read More

#Exclusive Content

#ApconiX #Drug safety #Interview

New podcast: Why is a target safety assessment so important?

The latest sponsored DDW Sitting Down With podcast is now live. Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to… Read More

#News

#ApconiX #Drug safety #Interview #Sitting Down With #Sitting Down With podcast

How a target safety assessment supports the drug development process

In the latest sponsored DDW Sitting Down With podcast Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to be modulated. The speakers outline… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Events #Interview #SLAS2023

Acquiring deeper insights and acceleration with AI

At IBM Research, a group of scientists and researchers from around the globe is working to support the power of the scientific method to invent what’s next for IBM, its clients, and the world. Joshua Smith, PhD, IBM TJ Watson Research Center, speaks with DDW’s Megan Thomas about AI, and… Read More

#Exclusive Content

#Drug discovery #Genetics / genomics #Interview #Precision medicine #RNA #RNA sequencing #Transcriptomics

How transcriptomics is driving drug discovery

Listen to this article on the DDW Podcast: Dr Stephen Barat, Senior Vice President and Therapeutics Division Head at HTG Molecular Diagnostics tells DDW how transcriptomics is driving drug discovery and precision medicines. DDW: Could you explain the process of transcriptomics?  SB: Transcriptomics is the study… Read More

#Exclusive Content

#Interview #Mental health #Neuroscience #Precision psychiatry #Psychiatry #Psychiatry Consortium #Target identification #Target validation

Target validation in psychiatry: addressing unmet therapeutic needs

The Psychiatry Consortium and the British Neuroscience Association recently published their ‘Guiding Principles for Robust Target Validation in Psychiatry’. Dr Ekta Patel, Psychiatry Consortium Partnership Manager, spoke to DDW’s Diana Spencer about how the guide can help researchers to create a target validation package and the need for new… Read More

#Exclusive Content

Neurons in the brain
#Antidepressants #Interview #Major depressive disorder #Neuropsychiatric disorders #Neuroscience #Precision medicine #Precision psychiatry #Psychiatry

Precision psychiatry: Transforming therapeutics for CNS disorders

Mike McCully, CEO of Gate Neurosciences, speaks to DDW’s Diana Spencer about the company’s pipeline of next-generation antidepressants and why this could be the most exciting time in the history of psychiatry. DS: How has our understanding of the brain developed in the last 70 years?  MM: Although our… Read More

#Exclusive Content

#3D chemistry #AI #Artificial intelligence (AI) #Biologics #Interview #Oncology #PharmEnable

Sitting down with… PharmEnable

Listen to this article on the DDW podcast: Reece Armstrong speaks to Natalia Mateu, Co-Founder, Jelena Aleksic, Co-Founder and Peter Curran, Chemoinformatics Scientist, about utilising 3D chemistry and AI to get small molecule therapies from the clinic to the bedside. RA: How is Pharmenable aiming… Read More

#Exclusive Content

Blood cells
#Haemophilia #Interview #Novo Nordisk #Rare disease

Novo Nordisk: positivity for haemophilia treatment  

DDW Editor Reece Armstrong speaks to Stephanie Seremetis, Chief Medical Officer, Rare Blood Disorders at Novo Nordisk to get her response to the company’s latest study results for its Mim8 antibody. Earlier this year, pharmaceutical company Novo Nordisk announced positive results from Phase I & II clinical trials… Read More

#Exclusive Content #Opinion

#Assay #Bioscience #Data #Drug discovery #Drug targets #Interview #Life sciences #Screening

Ask the expert: assisting researchers with hit-to-lead

Pelago Bioscience is a specialised CRO, focusing on its patented Cellular Thermal Shift Assay (CETSA), which can assess therapeutically relevant target engagement in cells or tissue of unmodified compounds against the native, full-length proteins of interest. Stina Lundgren, Principal Project Advisor, shared the company’s hit-to-lead expertise with Lu Rahman. CETSA… Read More

#Editor's Choice #Exclusive Content #News